BioCentury
ARTICLE | Company News

TorreyPines neurology news

September 29, 2008 7:00 AM UTC

TorreyPines will seek development partners for tezampanel, NGX426 and NGX267. Tezampanel, an AMPA/kainite receptor antagonist, has completed Phase II testing to treat migraine. NGX426, an oral prodrug of tezampanel, is in a Phase I trial to treat chronic pain that is expected to be completed by year end. NGX267, a cholinergic muscarinic acetylcholine receptor M1 (CHRM1)(HM1) agonist, is in Phase II testing to treat xerostomia secondary to Sjogren's syndrome.

TorreyPines plans to sell its preclinical AD genetics program, gamma-secretase modulator (GSM) programs and AD compounds phenserine, posiphen and bisnocymserine. Phenserine, which inhibits acetylcholinesterase (AChE) and beta amyloid, was discontinued after failing Phase III trials. Posiphen, a positive isomer of phenserine, completed Phase I trials. Bisnorcymserine, a butyrylcholinesterase inhibitor, is in preclinical development. ...